

Product Data Sheet

Product Name: Drospirenone-¹³C₃

Cat. No.: GC52420

Chemical Properties

Cas. No.

SMILES O=C1CC[C@@]2(C)C([C@@](C3)([H])[C@@]3([H])[C@]4([H])[C@]2([H])CC[C@@]5(C)[C@@]4([H])[C@@](C6)([H])[C@@]6([H])[C@@]57[¹³CH2][¹³CH2][¹³C](O7)=O)=C1


Formula C₂₁[¹³C]₃H₃₀O₃ M.Wt 369.5

Solubility Acetonitrile: soluble, DMSO: soluble Storage -20°C

General tips For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution: ship with blue ice All other available size: ship with RT, or blue ice upon request.

Structure



Background

Drospirenone-¹³C₃ is intended for use as an internal standard for the quantification of drospirenone

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

by GC- or LC-MS. Drospirenone is a synthetic progestogen.¹ *In vivo*, drospirenone inhibits spontaneous ovulation in rats ($ID_{50s} = 0.3\text{-}1.0$ mg/day) when administered orally or subcutaneously.² Drospirenone (0.5 mg/animal) administered six times per day maintains pregnancy in ovariectomized pregnant rats. It reduces serum testosterone and luteinizing hormone (LH) in cynomolgus monkeys in a dose-dependent manner. Drospirenone (10 mg/animal per day) also inhibits testosterone-induced growth of the seminal vesicles and prostate in castrated rats. Formulations containing drospirenone have been used as oral contraceptives.³

1.Pollow, K., Juchem, M., Elger, W., et al.Dihydrospirorenone (ZK30595): A novel synthetic progestagen - characterization of binding to different receptor proteinsContraception46(6)561-574(1992) 2.Muhn, P., Fuhrmann, U., Fritzemeier, K.-H., et al.Drospirenone: A novel progestogen with antimineralocorticoid and antiandrogenic activityAnn. N. Y. Acad. Sci.761(1)311-335(1995) 3.Apter, D., Zimmerman, Y., Beekman, L., et al.Bleeding pattern and cycle control with estetrol-containing combined oral contraceptives: Results from a phase II, randomised, dose-finding study (FIESTA)Contraception94(4)366-373(2016)

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA